WO2004014888A1 - Endiandric acid h derivate als c-maf inhibitoren zur verwendung gegen asthma - Google Patents
Endiandric acid h derivate als c-maf inhibitoren zur verwendung gegen asthma Download PDFInfo
- Publication number
- WO2004014888A1 WO2004014888A1 PCT/EP2003/007821 EP0307821W WO2004014888A1 WO 2004014888 A1 WO2004014888 A1 WO 2004014888A1 EP 0307821 W EP0307821 W EP 0307821W WO 2004014888 A1 WO2004014888 A1 WO 2004014888A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- alkyl
- alkenyl
- branched
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 19
- 102000007987 Proto-Oncogene Proteins c-maf Human genes 0.000 title claims abstract description 15
- 108010089507 Proto-Oncogene Proteins c-maf Proteins 0.000 title claims abstract description 15
- XYHDKVJBIKILGM-UHFFFAOYSA-N endiandric acid H Natural products C1=C2OCOC2=CC(C2=CC(C3CC4C(CC(O)=O)C5C=CC2C3C54)O)=C1 XYHDKVJBIKILGM-UHFFFAOYSA-N 0.000 title description 25
- 239000003112 inhibitor Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 241000018415 Beilschmiedia Species 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 208000024891 symptom Diseases 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 238000004113 cell culture Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 150000001408 amides Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 abstract description 4
- 208000010668 atopic eczema Diseases 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 108090000978 Interleukin-4 Proteins 0.000 description 18
- 102000004388 Interleukin-4 Human genes 0.000 description 17
- 229940028885 interleukin-4 Drugs 0.000 description 16
- 239000000126 substance Substances 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 7
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- NCJMIMSYHAESBZ-UHFFFAOYSA-N Endiandric acid A Natural products C12C3C4C=CC1C(CC(=O)O)C2CC3C=CC4C1=CC=CC=C1 NCJMIMSYHAESBZ-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 241000218195 Lauraceae Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- NCJMIMSYHAESBZ-ISPFPGQYSA-N endiandric acid a Chemical compound C1([C@@H]2C=C[C@@H]3C[C@H]4[C@@H]([C@H]5C=C[C@@H]2[C@@H]3[C@@H]45)CC(=O)O)=CC=CC=C1 NCJMIMSYHAESBZ-ISPFPGQYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- -1 methylenedioxy group Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108010084455 Zeocin Proteins 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- FIWGUWJZNRWGNC-LAPHNKNDSA-N endiandric acid Natural products C([C@@H]12)=C[C@H]3C(C(=O)O)=CC[C@H](C4)[C@H]3[C@H]1[C@@H]4[C@@H]2CC1=CC=C(OCO2)C2=C1 FIWGUWJZNRWGNC-LAPHNKNDSA-N 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940100602 interleukin-5 Drugs 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 2
- 101001023124 Drosophila melanogaster Myosin heavy chain, non-muscle Proteins 0.000 description 2
- OXHPUGDWCMBQGE-UHFFFAOYSA-N Endiandric acid B Natural products C12C3C4C=CC1C(CC=CC(=O)O)C2CC3C=CC4C1=CC=CC=C1 OXHPUGDWCMBQGE-UHFFFAOYSA-N 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000036427 bronchial hyperreactivity Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- OXHPUGDWCMBQGE-BKJMHZRVSA-N endiandric acid b Chemical compound C1([C@@H]2C=C[C@@H]3C[C@H]4[C@@H]([C@H]5C=C[C@@H]2[C@@H]3[C@@H]45)C/C=C/C(=O)O)=CC=CC=C1 OXHPUGDWCMBQGE-BKJMHZRVSA-N 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000002923 oximes Chemical group 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000604930 Endiandra Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007756 Ham's F12 Nutrient Mixture Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000039538 Maf family Human genes 0.000 description 1
- 108091067370 Maf family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000017954 Nuclear factor of activated T cells (NFAT) Human genes 0.000 description 1
- 108050007058 Nuclear factor of activated T cells (NFAT) Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012482 calibration solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000005712 elicitor Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000018711 interleukin-13 production Effects 0.000 description 1
- 230000022023 interleukin-5 production Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 244000045561 useful plants Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- Asthma is a disease of the immune system that manifests itself, for example, as bronchial asthma in the form of an acute, seizure-like shortness of breath with expiratory ventilation disability. So far, only medications that alleviate symptoms are available for the treatment of asthma, but not medications that inhibit the mechanism that is responsible for the expression of inflammatory mediators.
- These inflammatory mediators especially the cytokines interleukin-4 (IL-4), interleukin-13 (IL-13) and interleukin-5 (IL-5), are overexpressed in asthma and are responsible for inflammation, eosinophilia, mucus formation and bronchial hyperreactivity, that sustain the disease. The expression of these cytokines is increased in the lungs of asthmatics (Ray & Cohn, J. Clin. Invest.
- c-maf belongs to the Maf family, a family of leucine-containing zipper proteins, which is involved in the regulation of the expression of a number of genes.
- IL-4 + helper cells a subset of the CD4 + helper cells, c-maf, in synergy with NFAT (nuclear factor of activated T cells), transactivates the IL-4 promoter, which in turn leads to an increase in the cytokine concentration.
- NFAT nuclear factor of activated T cells
- An inhibitor of c-maf should therefore lower the cytokine concentration, whereby on the one hand a lower IL-4 level leads to a reduced IgE (immunoglobulin E) concentration, since IL-4 is crucial for the stimulation of B cells for the production of IgE is.
- IgE immunoglobulin E
- a reduction in IgE would result in decreased mast cell degranulation and release of histamine, serotonin and other inflammatory factors.
- Ho et al. J. Exp. Med., 1998, 10, 1859-1866 that the concentration of the TH2 phenotype is regulated in an autocrine way by IL-4.
- lowering the IL-4 level results in a decrease in this T cell type, which in turn shifts the balance between TH1 and TH2 towards TH1.
- Genes that are selectively expressed in TH2 cells are therefore preferred targets for therapeutic use to selectively influence the inflammatory component in asthma and allergy.
- IL-4 and IL-5 antibodies are currently being tested in clinical trials (Foster et al., Trends Mol. Med., 2002, 8, 162). Selective therapeutics are expected to replace widespread glucocorticoid therapy, which has so far been the only way to curb the inflammatory response in asthma.
- n 1, as endiandric acid B.
- the compounds are obtainable from extracts from the lauraceae plant family, especially from the genera Endiandra and Beilschmiedia (Ban michayake et al., Aust. J. Chem., 1981, 34, 1655-67; Banfield et al., Aust. J. Chem., 1994, 47, 587-607).
- Bannesayake et al. describe the dihydro and tetrahydro derivatives of endiandric acid A, obtainable by partial or complete reaction with hydrogen in the presence of Pd / C.
- Banfield et al. describe endiandric acid A substituted on the phenyl radical by a methylenedioxy group.
- Acid group is functionalized, for example as CH 2 OSiPh 2 t-Bu, CHaBr, CH 2 CN, esterified to CO 2 CH 3 , or reduced to the aldehyde CHO or the alcohol CH 2 OH (Nicolaou et al., J. Am. Chem. Soc, 1982, 104, 5555-5557 and 5560-5562).
- the object of the present invention is to provide novel endiandric acid derivatives.
- the present invention therefore relates to a compound of the formula (I)
- R ⁇ and R2 independently of one another 0.0 H or 1.0 a -O-Ci-Cß-alkyl-, -O-C2-C6-alkenyl-, -O-C2-C6-alkynyl- or -O-Cß-Cio-aryl-
- Alkyl, alkenyl and alkynyl groups are optionally mono- or disubstituted by:
- the invention preferably relates to a compound of the formula (II)
- radicals R-j to R4 are as defined above.
- C 1 -C 6 -alkyl means a straight-chain or branched alkyl having 1 to 6 C atoms, preferably having 1 to 4 C atoms, e.g. Methyl, ethyl, i-propyl, tert-butyl and hexyl.
- C2-C6-alkenyl means a straight-chain or branched alkenyl with 2 to 6 C atoms, which is mono-, di- or trisaturated, e.g. Allyl, crotyl, 1-propenyl, penta-1, 3-dienyl and pentenyl.
- C2-C6 ⁇ alkynyl means a straight-chain or branched alkynyl having 2 to 6 carbon atoms, which is mono- or di-unsaturated, e.g. Propynyl, butynyl and pentynyl.
- c 6 " c 10" aryl means an aryl group with 6 to 10 carbon atoms, for example phenyl, benzyl or 1- or 2-naphthyl, which can also be substituted, for example by halogen, such as chlorine, bromine, fluorine or by alkyl with 1-4 C atoms, preferably methyl, by hydroxy, by alkoxy with 1-4 C atoms, in particular methoxy or by trifluoromethyl.
- Ci-Cß-alkylene means an alkylene group with 1 to 6 carbon atoms, preferably with 1 to 4 carbon atoms, for example methylene, ethylene, i-propylene, tert-butylene and hexylene.
- Rl and R2 are preferably H or a group -O - [(Cj-C6) alkyl] -O-, particularly preferably -OCH 2 -O-.
- R3 is preferably H.
- R4 is preferably COOR3, with R3 preferably H.
- the invention particularly preferably relates to a compound of the formula (III)
- the invention further particularly preferably relates to a compound of the formula (IV), which is referred to below as endiandric acid H:
- the compounds of the formula (I) according to the invention contain a tetracyclic ring system with a phenyl radical which, in contrast to the compounds described hitherto, is in conjugation with one of the two double bonds in the tetracyclic ring system, and have an additional hydroxyl group. Due to their different chemical structure, the compounds of formula (I) have new physico-chemical, biological and pharmacological properties.
- the invention further relates to a process for the preparation of the compound of formula (I), characterized in that
- the invention further relates to a process for the preparation of a compound of formula (IV), characterized in that
- the Beilschmiedia fulva plant or one of its variants or mutants is first grown under suitable conditions until endiandric acid H of the formula (IV) accumulates in the plant material.
- the Beilschmiedia fulva plant, its mutants and / or variants are preferably grown on suitable soils in a tropical or subtropical climate. Plant production is particularly preferably carried out under tropical conditions, for example at a temperature between 18 and 35 ° C. and at a humidity of greater than or equal to 70%, preferably 70-90%.
- the compound of formula (IV) For the extraction of the compound of formula (IV) from living cells of the Beilschmiedia fulva plant, these are first transferred to a suitable nutrient solution and grown until the compound of formula (IV) according to the invention accumulates in the medium.
- the cell cultures are preferably created from callus cultures.
- the nutrient media also consist of at least one carbon source, for example sucrose, and at least one nitrogen source, for example a nitrate or ammonium salt.
- Beilschmiedia fulva is a tree from the Lauraceae family. In the Lauraceae family there are many evergreen tropical herbs and useful plants. The distribution area of the Lauraceae is the entire tropics: The sample of the plant Beilschmiedia fulva, PLA 101037, was in Gabon, especially in the area around la Makande collected in the treetop area of the rainforest. The sample was collected in the immediate vicinity of Makande Research Field Station (coordinates 0 ° 40 '860 "S - 11 ° 54'750" E). Beilschmiedia fulva is a tree that can grow up to 30 m high and is therefore part of the treetop region of the rainforest. The leaves are blue-green, the fruits are red. The stem, which is cylindrical in shape at the base, is covered with a little bark of brittle consistency and has a brown-reddish color. The layer of bark is about 4-5 mm thick and has a characteristic smell.
- Endiandric acid H can vary depending on the location, e.g. Soil quality, temperature, humidity, incidence of light vary.
- the process according to the invention can be used for the extraction and isolation in a wide range of plant material to be extracted, for example on a laboratory scale (100 g to 1 kg of dry plant material) up to an industrial scale (100 to> 1000 kg).
- the Beilschmiedia fulva plant can be cultivated outdoors or preferably in a greenhouse.
- cell cultures of Beilschmiedia fulva can be used to produce the compounds of the invention.
- cultivation takes place in several stages, i.e. one or more precultures are first prepared in a suitable liquid medium, with which the main culture can then be inoculated.
- the starting material usually consists of callus cultures.
- airlift or bubble column reactors, and blade or propeller agitators are used to mix the cultures.
- the cells can grow as single cells or branched or unbranched cell aggregates or chains.
- the metabolite production can be induced by stimulation with exogenous factors, for example heavy metal salts or vegetable elicitors.
- the product formation in the plant cell culture can be monitored on the basis of the pH value of the cultures and by chromatographic methods, such as, for example, thin-layer chromatography, HPLC or testing of the biological activity.
- Endiandric acid H of formula (IV) can also be contained in other parts of the plant in addition to the bark.
- the endiandric acid H of the formula (IV) according to the invention is isolated and purified from the plant or the culture medium by known methods, taking into account the chemical, physical and biological properties of the natural products.
- HPLC can be used to test the concentration of the compounds according to the invention in the starting material or in the individual isolation stages, the amount of the substance formed advantageously being compared with a calibration solution.
- the Beilschmiedia fulva plant is harvested, the leaves, stems, wood, bark or roots being collected first and separated into parts of the plant, still in a fresh state or dried and then also with the plant material an optionally water-containing organic solvent extracted.
- the bark is preferably extracted to isolate the compounds according to the invention.
- the extracts are combined, diluted with water and extracted with a suitable water-immiscible organic solvent, for example with n-butanol.
- a suitable water-immiscible organic solvent for example with n-butanol.
- the subsequently separated organic phase is optionally in the
- the endiandric acid H precipitates, the lipophilic impurities remain dissolved and are removed by conventional solid / liquid phase separations.
- the precipitate containing the endiandric acid H is lyophilized. The lyophilisate is further purified.
- Endiandric acid H is further purified by chromatography on suitable materials, preferably e.g. on molecular sieves, on normal phase supports, such as. As silica gel, aluminum oxide, on ion exchangers or on adsorber resins or on reversed phases (reversed phase, RP).
- suitable materials preferably e.g. on molecular sieves, on normal phase supports, such as. As silica gel, aluminum oxide, on ion exchangers or on adsorber resins or on reversed phases (reversed phase, RP).
- the endiandric acid H is separated off with the aid of this chromatography.
- Endiandric acid H is chromatographed using buffered aqueous solutions or mixtures of aqueous and organic solutions.
- aqueous and organic solutions are understood to mean all water-miscible organic solvents, preferably methanol, 2-propanol and acetonitrile, in a concentration of 10 to 90% solvent, preferably 15 60% solvent, or all buffered aqueous solutions containing organic Solvents are miscible.
- Endiandric acid H is separated using reversed phase chromatography, for example on MCI® (adsorber resin from Mitsubishi, Japan) or Amberlite XAD® (TOSOHAAS), on other hydrophobic materials, such as on RP-8 or RP-18 Phases or on polyamides.
- reversed phase chromatography for example on MCI® (adsorber resin from Mitsubishi, Japan) or Amberlite XAD® (TOSOHAAS), on other hydrophobic materials, such as on RP-8 or RP-18 Phases or on polyamides.
- the separation can be carried out with the aid of gel chromatography or normal phase chromatography, for example on silica gel or aluminum oxide.
- Endiandric acid H is chromatographed using buffered or acidified aqueous solutions or mixtures of aqueous solutions with alcohols or other water-miscible organic solvents.
- Propanol and acetonitrile are preferably used as the organic solvent.
- Buffered or acidified aqueous solutions are understood to mean, for example, water, phosphate buffer, citrate buffer, ammonium acetate in a concentration of 1 mM to 0.5 M, preferably 10 mM, and formic acid, acetic acid, trifluoroacetic acid or all commercially available acids known to those skilled in the art, preferably in one Concentration from 0.01 to 3%.
- Chromatography is carried out using a gradient which begins with 100% aqueous buffer and ends with 100% solvent, preferably a linear gradient of 10 to 60% 2-propanol or acetonitrile is used.
- Gel chromatography is performed on polyacrylamide or mixed polymer gels, e.g. Biogel-P 2® (from Biorad), Fractogel TSK HW 40® (from Merck, Germany or Toso Haas, USA) or to Sephadex® (from Pharmacia, Uppsala, Sweden).
- Biogel-P 2® from Biorad
- Fractogel TSK HW 40® from Merck, Germany or Toso Haas, USA
- Sephadex® from Pharmacia, Uppsala, Sweden.
- a further purification step for the compounds according to the invention is crystallization.
- endiandric acid H of formula (IV) crystallizes from organic solvents and from mixtures of water with organic
- the crystallization is carried out in a manner known per se, for example by concentrating or cooling saturated solutions.
- Endiandric acid H of the formula (IV) is stable in the solid state and in solutions in the pH range between 3 and 8, in particular 4 and 6.
- the compound of formula (I) can be derivatized by known methods (J. March, Advanced Organic Synthesis, 4 th Edition, John Wiley & sons. 1992).
- the carboxyl function can be esterified or reduced to the primary alcohol, or it can be converted to an amide.
- the reduction of carbonyl groups can be carried out using metal hydrides, such as aluminum hydrides or boron hydrides.
- a reduction to the saturated compounds can Example can be achieved with hydrogen in the presence of suitable catalysts.
- the hydroxy function can be etherified.
- Physiologically tolerable salts of compounds of the formula (I) are understood to mean both their organic and inorganic salts, as described in Remington's Pharmaceutical Sciences (17th edition, page 1418 (1985)). Because of the physical and chemical stability and the solubility, sodium, potassium, calcium and ammonium salts, among others, are preferred for acidic groups.
- salts include hydrochloric acid, sulfuric acid, phosphoric acid or carboxylic acids or sulfonic acids, e.g. Acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid and p-toluenesulfonic acid are preferred.
- the present invention encompasses all stereoisomeric forms of the compounds of formula (I).
- the invention includes all possible enantiomers and diastereomers, as well as mixtures of two or more stereoisomeric forms, for example mixtures of enantiomers and / or diastereomers, in all ratios.
- Enantiomers are the object of the invention in all ratios in enantiomerically pure form, both as left-handed and as right-handed antipodes, R and S configurations, in the form of racemates and in the form of mixtures of the two enantiomers.
- a cis / trans isomerism both the cis form and the trans form and mixtures of these forms are the subject of the invention in all proportions.
- the compounds of the formula (I) according to the invention are suitable for use as medicaments in human and / or veterinary medicine.
- the invention therefore further relates to a medicament containing at least a compound of formula (I) and one or more physiologically suitable excipients.
- Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, dragées, (micro) capsules, suppositories, syrups, emulsions, suspensions, aerosols, drops or injectable solutions in ampoule form, and also preparations with protracted active ingredient release, in the production of which they are customary physiologically suitable auxiliaries such as carriers, explosives, binders, coatings, swelling agents, lubricants or lubricants, flavorings, sweeteners or solubilizers are used. As commonly used carriers or auxiliaries are e.g.
- the oral dosage units can be microencapsulated to delay or extend delivery, such as by coating or embedding the active ingredient in particulate form in suitable polymers, waxes, or the like.
- the pharmaceutical preparations are preferably produced and administered in dosage units, each unit containing as active ingredient a specific dose of at least one compound of the formula (I).
- Dosage units such as tablets, capsules and suppositories, this dose can be up to 1 g, preferably about 0.1 to 200 mg, and for injection solutions in ampoule form up to 1 g, preferably about 0.1 to 100 mg.
- the daily dose to be administered depends on the body weight, age, gender and condition of the mammal. Under certain circumstances, however, higher or lower daily doses may also be appropriate.
- the administration of the daily dose can both by single administration in the form of a single dosage unit or in several smaller dosage units as well as by multiple administration of divided doses at certain intervals.
- the medicaments according to the invention are prepared by bringing one or more compounds of the formula (I) into a suitable dosage form with one or more physiologically suitable auxiliaries.
- the invention further relates to the use of a compound of formula (I) for the manufacture of a medicament, in particular for the treatment of allergic diseases, asthmatic diseases, accompanying inflammatory symptoms of asthma and / or diseases treated by inhibiting c-maf and NFAT can be.
- the zipper protein c-maf represents the test target. It plays an important role in the release of inflammatory mediators, especially IL-4, and thus in the manifestation of inflammatory symptoms in asthma and allergies, c-maf is therefore an important therapeutic target molecule for asthma, especially if it is allergic. In the test, the activity of c-maf is measured based on the transcription rate of IL-4. Compounds that interfere with the binding of the two transcription factors c-maf and NFAT lead to a reduced expression of luciferase (read-out) by suppressing the transcription of a human IL-4 promoter / luciferase construct.
- Example 1 Plant production (collecting the seeds, sowing and growing and harvesting conditions).
- Beilschmiedia fulva seeds were collected after ripening and sown in the greenhouse for further cultivation of the plants.
- the optimal temperature was approx. 28 ° C with a humidity of 70-90%.
- the plants were cultivated for several months to years until the bark and other suitable parts of the plant were harvested.
- Example 2 Preparation of a primary extract from Beilschmiedia fulva.
- Pieces of the bark from Beilschmiedia fulva were collected fresh and then air-dried at approx. 40 ° C. After drying, 100 g of dry material were ground and extracted with 1 L of methanol at 40 ° C for 8 hours with stirring. After the extraction had ended, the plant residues were filtered off and the methanolic extract was evaporated to almost dryness under vacuum. The residue was resuspended with a little water and then freeze-dried. The resulting primary extract could be stored at + 4 ° C to -20 ° C or used for further isolation as in Example 3. To test the biological activity, tannins and other strongly hydrophilic or lipophilic interfering substances were removed from the primary extract by means of chromatography on polyamide and on polystyrene adsorber resin.
- Example 3 Isolation of Endiandric acid H from the Beilschmiedia fulva plant.
- Example 2 harvested, crushed in a mill, stirred with 1 L of methanol for 16 hours and then filtered.
- the active ingredient-containing, methanolic solution is concentrated in vacuo; the dry weight is 7.0 g.
- the concentrate is applied to a prepared glass column (BPG 100, 4 L internal volume, Pharmacia Biotech), which is filled with approx. 0.5 L MCI-Gel® CHP-20P material (adsorbent resin from Mitsubishi Chemicals, Japan) , Elution is carried out with a gradient of 100% water to 100% acetonitrile.
- the column flow rate 50 mL per minute
- fractions 50 mL each
- fractions active in the bioassay fractions 18-21. Concentration in vacuo and freeze drying give 102 mg of light brown powder.
- Example 4 Purification of endiandric acid H by means of reversed phase HPLC.
- the 102 mg of the powder obtained according to Example 3 were applied to a LUNA® 10 ⁇ C18 (2) column (size: 21.2 mm ⁇ 250 mm, from Phenomenex, Germany) and with a gradient of 3% to 60% acetonitrile chromatographed in 0.1% ammonium acetate / water for 60 minutes.
- the flow through of the eluent is 33 ml / min, the fraction size is 33 ml.
- Fractions 24 and 25 contain the endiandric acid H. The lyophilization of the fractions mentioned gives 3.7 mg of pure substance (purity> 95%).
- Fragmentation obtained the following ions: 349 amu (M + H-H2O) to 331 amu (-H2O), 303 amu (-CH2O2), 289 amu (-C2H4O2).
- Fragmentation obtained the following ions: 365 amu (MH) - to 321 amu (-CO2), 267 amu (-C5H6O2) 227 amu (-C ⁇ HinC ⁇ ). 15 amu (-C9H10O2) and smaller
- the human IL-4 promoter (-6635 to +66) was used for cloning
- Luciferase reporter gene construct produced (IL-4 luc).
- the cDNA of full-length murine nuclear factor of activated T cells (NFAT) was cloned into another vector.
- CHO-K1 cells were then transfected with both vectors (IL-4 luc / NFAT) by means of electroporation.
- a G418 selection process was used to obtain a monoclonal IL-4 luc / NFAT cell line.
- full-length murine c-maf cDNA was cloned into a suitable vector and the generated IL-4 luc / NFAT cell line was thus co-transfected.
- the resulting monoclonal cell line carries all three vectors (c-maf / IL-4 luc / NFAT) and was used for the screening.
- the cells were cultivated in the logarithmic growth phase at 37 ° C., 5% CO 2 in tissue culture bottles of the area 225 cm 2 in the following medium: Ham's F-12 Nutrient Mixture, supplemented with 10% fetal calf serum, 1% antibiotic / antifungal, 300 ⁇ g / ml Geneticin and 300 ⁇ g / ml Zeocin.
- CHO-K1 cells 16 hours before the assay, CHO-K1 cells were harvested by trypsinization, washed once with PBS w / o Ca and Mg, resuspended in Ham's F-12 medium, which additionally contains 10% fetal calf serum, 1% antibiotic / antifungal, 0.001% Pluronic, Contained 300 ug / ml Geneticin and 300 ug / ml Zeocin, and then quantified using a hemocytometer. The cells were plated on microtiter plates in a cell concentration of 2000 cells per well in 2 ⁇ l medium. The cells are incubated overnight at 37 ° C and 5% CO 2 .
- DMSO fetal calf serum
- 1% antibiotic / antifungal Gibco BRL, No. 15240-062
- 300 ⁇ g / ml Geneticin 300 ⁇ g / ml Zeocin
- the CHO-K1 cells were mixed with 1 ⁇ l of the test substance solutions prepared in this way and then incubated for 8 hours at 37 ° C. and 5% CO 2 .
- the final concentration of DMSO was a maximum of 0.83% per well.
- the cells are mixed with 3 ⁇ l Bright-Glow TM Luciferase Assay Reagent (Promega Corporation, Madison, USA) per well. The plates are then placed in the dark for 30 minutes and then measured on the CyBiTM Lumax Reader. As a positive control, DMSO was also tested in a final concentration of 33.3%. In addition, the positive controls were normalized to a concentration of 0.83%.
- Each test plate contains 64 negative controls (wells without added substance) and 64 positive controls (wells in which the cells were killed with 1 ⁇ l DMSO). The inhibition is calculated as follows:
- Endiandric acid H shows an ICso value of 1.5 ⁇ M in the bioassay.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004526742A JP4598523B2 (ja) | 2002-08-02 | 2003-07-18 | 喘息に使用するc−maf阻害剤としてのエンジアンドリック酸h誘導体 |
AU2003250099A AU2003250099B2 (en) | 2002-08-02 | 2003-07-18 | Endiandric acid H derivatives as c-maf inhibitors for using against asthma |
EP03784025A EP1529040B1 (de) | 2002-08-02 | 2003-07-18 | Endiandric acid h derivate als c-maf inhibitoren zur verwendung gegen asthma |
DE50302084T DE50302084D1 (de) | 2002-08-02 | 2003-07-18 | Endiandric acid h derivate als c-maf inhibitoren zur verwendung gegen asthma |
CA2493483A CA2493483C (en) | 2002-08-02 | 2003-07-18 | Endiandric acid h as c-maf inhibitors derivatives for use against asthma |
MXPA05000387A MXPA05000387A (es) | 2002-08-02 | 2003-07-18 | El acido endiandrico h como derivados inhibidores de c-maf para su uso contra el asma. |
AT03784025T ATE314359T1 (de) | 2002-08-02 | 2003-07-18 | Endiandric acid h derivate als c-maf inhibitoren zur verwendung gegen asthma |
BR0313199-8A BR0313199A (pt) | 2002-08-02 | 2003-07-18 | Derivados h de ácido endiândrico como inibidores de c-maf para o emprego contra asma |
IL166439A IL166439A (en) | 2002-08-02 | 2005-01-23 | Endiandric acid h derivatives as c-maf inhibitors for using against asthma, their preparation and pharmaceutical compositions comprising them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10235624A DE10235624A1 (de) | 2002-08-02 | 2002-08-02 | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
DE10235624.6 | 2002-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004014888A1 true WO2004014888A1 (de) | 2004-02-19 |
Family
ID=30469404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/007821 WO2004014888A1 (de) | 2002-08-02 | 2003-07-18 | Endiandric acid h derivate als c-maf inhibitoren zur verwendung gegen asthma |
Country Status (13)
Country | Link |
---|---|
US (1) | US7019028B2 (de) |
EP (1) | EP1529040B1 (de) |
JP (1) | JP4598523B2 (de) |
AT (1) | ATE314359T1 (de) |
AU (1) | AU2003250099B2 (de) |
BR (1) | BR0313199A (de) |
CA (1) | CA2493483C (de) |
DE (2) | DE10235624A1 (de) |
DK (1) | DK1529040T3 (de) |
ES (1) | ES2254980T3 (de) |
IL (1) | IL166439A (de) |
MX (1) | MXPA05000387A (de) |
WO (1) | WO2004014888A1 (de) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9702878B2 (en) | 2012-04-09 | 2017-07-11 | Fundació Institut de Recera Biomèdica (IRB Barcelona) | Method for the prognosis and treatment of cancer metastasis |
US10006091B2 (en) | 2012-06-06 | 2018-06-26 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
US10047398B2 (en) | 2010-10-06 | 2018-08-14 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
US10114022B2 (en) | 2012-10-12 | 2018-10-30 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
US11596642B2 (en) | 2016-05-25 | 2023-03-07 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
US11654153B2 (en) | 2017-11-22 | 2023-05-23 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1944361A1 (de) | 2007-01-11 | 2008-07-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methode zur Kultivierung von Monozyten |
WO2015019125A1 (en) * | 2013-08-05 | 2015-02-12 | Societe De Developpement Et De Recherche Industrielle | Molecular targets for the treatment of wounds, in particular chronic wounds |
-
2002
- 2002-08-02 DE DE10235624A patent/DE10235624A1/de not_active Withdrawn
-
2003
- 2003-07-18 AT AT03784025T patent/ATE314359T1/de active
- 2003-07-18 ES ES03784025T patent/ES2254980T3/es not_active Expired - Lifetime
- 2003-07-18 DK DK03784025T patent/DK1529040T3/da active
- 2003-07-18 EP EP03784025A patent/EP1529040B1/de not_active Expired - Lifetime
- 2003-07-18 JP JP2004526742A patent/JP4598523B2/ja not_active Expired - Fee Related
- 2003-07-18 DE DE50302084T patent/DE50302084D1/de not_active Expired - Lifetime
- 2003-07-18 AU AU2003250099A patent/AU2003250099B2/en not_active Ceased
- 2003-07-18 CA CA2493483A patent/CA2493483C/en not_active Expired - Fee Related
- 2003-07-18 WO PCT/EP2003/007821 patent/WO2004014888A1/de active IP Right Grant
- 2003-07-18 MX MXPA05000387A patent/MXPA05000387A/es active IP Right Grant
- 2003-07-18 BR BR0313199-8A patent/BR0313199A/pt not_active Application Discontinuation
- 2003-07-25 US US10/627,850 patent/US7019028B2/en not_active Expired - Fee Related
-
2005
- 2005-01-23 IL IL166439A patent/IL166439A/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
BANFIELD J. E., ET AL.: "Constituents of Some Species of Beilschmiedia and Endiandra (Lauraceae): New Endiandric Acid and Benzopyran Derivatives Isolated from B. oligandra", AUST. J. CHEM., vol. 47, 1994, pages 587 - 607, XP002123244 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11072831B2 (en) | 2010-10-06 | 2021-07-27 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
US10047398B2 (en) | 2010-10-06 | 2018-08-14 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of breast cancer metastasis |
US9702878B2 (en) | 2012-04-09 | 2017-07-11 | Fundació Institut de Recera Biomèdica (IRB Barcelona) | Method for the prognosis and treatment of cancer metastasis |
US10866241B2 (en) | 2012-04-09 | 2020-12-15 | Institucio Catalana De Recerca I Estudis Avancats | Method for the prognosis and treatment of cancer metastasis |
US10006091B2 (en) | 2012-06-06 | 2018-06-26 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
US11352673B2 (en) | 2012-06-06 | 2022-06-07 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
US10114022B2 (en) | 2012-10-12 | 2018-10-30 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
US11041861B2 (en) | 2012-10-12 | 2021-06-22 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
US11041213B2 (en) | 2012-10-12 | 2021-06-22 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
US11840740B2 (en) | 2012-10-12 | 2023-12-12 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
US11892453B2 (en) | 2012-10-12 | 2024-02-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
US11596642B2 (en) | 2016-05-25 | 2023-03-07 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
US11654153B2 (en) | 2017-11-22 | 2023-05-23 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
Also Published As
Publication number | Publication date |
---|---|
BR0313199A (pt) | 2005-06-21 |
MXPA05000387A (es) | 2005-03-23 |
EP1529040B1 (de) | 2005-12-28 |
CA2493483C (en) | 2011-09-20 |
DE50302084D1 (de) | 2006-02-02 |
US7019028B2 (en) | 2006-03-28 |
DE10235624A1 (de) | 2004-02-19 |
ES2254980T3 (es) | 2006-06-16 |
IL166439A0 (en) | 2006-01-15 |
AU2003250099A1 (en) | 2004-02-25 |
JP2006503006A (ja) | 2006-01-26 |
AU2003250099B2 (en) | 2008-12-18 |
DK1529040T3 (da) | 2006-05-08 |
US20040138313A1 (en) | 2004-07-15 |
ATE314359T1 (de) | 2006-01-15 |
CA2493483A1 (en) | 2004-02-19 |
EP1529040A1 (de) | 2005-05-11 |
JP4598523B2 (ja) | 2010-12-15 |
IL166439A (en) | 2009-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69505946T2 (de) | Antiparasitäre pyrrolobenzoxazin verbindungen | |
EP1529040B1 (de) | Endiandric acid h derivate als c-maf inhibitoren zur verwendung gegen asthma | |
CN110724121B (zh) | 铁皮石斛叶中的一种联苄类衍生物及其制备方法和用途 | |
DE68903907T2 (de) | Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen. | |
DE60029982T2 (de) | Antimykotische enediyne | |
EP1280812A1 (de) | Cyclipostine, verfahren zu ihrer herstellung und verwendung derselben | |
WO2002046152A2 (de) | Coniosetin und derivate davon, verfahren zur herstellung und verwendung derselben | |
EP1341778B1 (de) | Klainetine und ihre derivate, verfahren zu ihrer herstellung und verwendung derselben | |
EA002644B1 (ru) | Производные 4-циано-4-деформилсордарицина | |
DE10111682A1 (de) | Caloporosid-Derivate, Verfahren zu deren Herstellung und deren Verwendung | |
WO2003002549A1 (de) | Eurotinone und derivate davon, verfahren zu ihrer herstellung und verwendung derselben | |
KR100710010B1 (ko) | 호박씨 추출액의 제조방법 및 항암제로서의 용도 | |
KR101813112B1 (ko) | 신규한 세스퀴터펜 유도체, 이의 제조방법 및 이를 유효성분으로 하는 골 질환의 예방 또는 치료용 약학조성물 | |
WO2005072711A2 (de) | Verfahren zur herstellung von sorbicillacton a | |
DE2743493A1 (de) | Amine, verfahren zu deren herstellung und sie enthaltende arzneimittel | |
EP1532129A1 (de) | Sorbicillacton-a-derivate zur behandlung von tumor- und viruserkrankungen | |
EP1529025B1 (de) | Polyisoprenyl-benzophenon-derivate, verfahren zu ihrer herstellung und verwendung derselben | |
RU2188547C2 (ru) | Композиция для повышения продуктивности сахарной свеклы | |
CN118255759A (zh) | 一种小檗碱-蒽醌药物共晶、小檗碱-蒽醌-黄芩苷三元共晶复配剂及合成方法和应用 | |
AT233310B (de) | Coccidiostatische Zubereitungen | |
CH437343A (de) | Verfahren zur Herstellung von 5-Nitrofurfuryliden-carbazaten | |
DE1518334B2 (de) | Substituierte benzylamine und ihre salze sowie verfahren zu ihrer herstellung | |
DE2058915A1 (de) | Verfahren zur Herstellung von Oudenon | |
JP2003026684A (ja) | Mb7056a物質およびmb7056b物質、その製造法並びにその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/000387 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003784025 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2493483 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 166439 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003250099 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004526742 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003784025 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003784025 Country of ref document: EP |